PRESS RELEASE: Geratherm Medical AG: New SRA Technology detects atrial fibrillation at an early stage and prevents …

PRESS RELEASE: Geratherm Medical AG: New SRA Technology detects atrial fibrillation at an early stage and prevents strokes

DGAP-News: Geratherm Medical AG / Key word(s): Study Geratherm Medical AG: New SRA Technology detects atrial fibrillation at an early stage and prevents strokes

03.03.2014 / 09:28

=--------------------------------------------------------------------

Corporate News

New SRA Technology detects atrial fibrillation at an early stage and prevents strokes

- Results of a multicenter study including 225 participants just published. Study Sponsor: Sanofi-Aventis, Study conduction: Cardiology Platform Hessen

- SRA-Technology from apoplex medical convinces in the detection of paroxysmal atrial fibrillation - information about a risk for a threatening stroke prepares the way for early diagnose and preventive measures

Apoplex, Geratherm, Pirmasens, 3 March 2014. Cardiological practices in Hessen investigated in a multicenter study including 225 participants over three years the use of a SRA (Stroke Risk Analysis)-based ECG analysis for paroxysmal atrial fibrillation. The SRA-procedure developed by apoplex medical technologies GmbH, Pirmasens, analyses ECG data fully automatic with the goal, to detect atrial fibrillation at an early stage for preventing threatening strokes by applying appropriate therapeutic measures.

The results of the study were published on 28 February 2014 by the journal PLOS ONE in San Francisco, USA. The study, sponsored by Sanofi-Aventis, compares conventional ECG examinations with the SRA procedure under conditions of the daily routine in doctor's practices. In 23 from 54 patients without fibrillation episodes, SRA detected a risk for paroxysmal atrial fibrillation (sensitivity 42.6%, specificity 99.0%). Conventional ECG analysis did not indicate atrial fibrillation in these cases. Cardiologically confirmed fibrillation episodes were detected with a sensitivity of 99.2% and a specificity of 99.2%. With these results in the context of a cardiological study, the SRA-technology has impressively proven its excellent performance to detect unknown paroxysmal atrial fibrillation.

See the original post here:
PRESS RELEASE: Geratherm Medical AG: New SRA Technology detects atrial fibrillation at an early stage and prevents ...

Related Posts

Comments are closed.